Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 6129

Tokyo space startup Gitai Japan successfully conducted a technology demonstration of its autonomous robotic arm inside the International Space Station last week, a key milestone as the company prepares to provide robotics as a service in space.

The S1 robotic arm performed two tasks: operating cables and switches, and assembling structures and panels. These tasks — common crew activities — can be used in a general-purpose way for a range of in-space activities. The successful demo raised what NASA calls the “technology readiness level” of the Gitai robot to TRL 7. There are nine TRLs in total and hitting all of them will be critical for Gitai commercializing its robots.

The demonstration was performed inside space company Nanoracks’ Bishop Airlock, the world’s first (and only) commercial airlock to be attached to the exterior of the station. Nanoracks — which announced plans last week to launch a fully private commercial space station with Voyage Space and Lockheed Martin — also furnished on-orbit operations, data downlink and the launch opportunity.

Read more | >

“…The authors modified a well-used climate model for exoplanet research and applied it to the planet in Dune. The work was carried out in their spare time and is intended as an appropriate outreach piece to demonstrate how climate scientists use mathematical models to better understand our world and exoplanets…”

Looks like the Kingdom of Jordan to me. 😉

Is Dune scientifically plausible? We ran a climate model to find out.

Read more | >

Facebook’s response, however, isn’t about how it should change its business model. Instead of any degree of self-awareness, the company has decided it’s going to push back on its critics and try to change the subject. Facebook isn’t actually trying to change any of the things that are wrong with Facebook.

Zuckerberg did talk a lot about the metaverse and said he plans to give more details later this week at Connect, the company’s developer conference.

To be fair, Zuckerberg did say that the company is “on track to spend more than $5 billion on safety and security in 2021.” That might sound impressive, but considering the company made $115 billion in the last 12 months, it’s barely anything. It’s only half of what Facebook says it plans to spend on building the metaverse.

Read more | >

Can intelligence be taught to robots? Advances in physical reservoir computing, a technology that makes sense of brain signals, could contribute to creating artificial intelligence machines that think like us.

In Applied Physics Letters, researchers from the University of Tokyo outline how a robot could be taught to navigate through a maze by electrically stimulating a culture of connected to the machine.

These nerve cells, or neurons, were grown from living cells and acted as the physical reservoir for the to construct coherent signals.

Read more | >

Researchers have confirmed cases of the disease among two unconnected West African populations of chimpanzees, in Guinea-Bissau and the Ivory Coast.

Analysis published in the journal Nature shows the strains of leprosy are different, and both are uncommon among humans.

The origins of the infections are unclear, but the research team – led by the University of Exeter and the Robert Koch Institute – say the findings show leprosy is probably circulating in more wild animals than was previously suspected, either as a result of exposure to humans or other unknown environmental sources.

Read more | >

Cell culture is an essential in vitro experimental tool. An attempt to recapitulate the body in a dish, in two and three dimensions, it has provided the basis for decades of research and probably thousands of PhDs. When it goes wrong, however, whether through accident, infection, misidentification, cross-contamination or uncontrolled differentiation (for stem cells), it can be very stressful, especially in the case of longer-term experiments or when using hard-to-replace cell lines. Another important consideration is reproducibility, which is an acknowledged life sciences industry issue. A 2015 PLOS Biol ogy study, for example, reported in an analysis of previous studies that the prevalence of irreproducible research was over 50% – equivalent to USD $28 billion per year on irreproducible preclinical research.1 Inconsistencies in cell culture approaches are a potential issue in this regard, as if cells are not maintained or used in a consistent way, or are contaminated with an infection (like mycoplasma), this can negatively impact results and make it more difficult to reproduce and/or accurately interpret data.

“Quality control (QC) is a key part of assuring the quality of outputs from any cell culture process, and is an essential part of assuring reproducibility of scientific quality in research as well as assurance of the quality and safety of cell culture-derived products,” comments Glyn N Stacey, International Stem Cell Banking Initiative, Cambridge, UK, and the Institute for Stem Cells and Regeneration and National Stem Cell Resource Centre, Chinese Academy of Sciences, Beijing, China. “These topics are currently very much in the minds of journal editors, research funders and regulators and are thus of crucial significance to researchers.”

This article will look at these different aspects of cell culture quality control and the types of protocols that can be implemented to help ensure reliable and reproducible results.

Read more | >

The comprehensive maps of the entire observable Universe is now in development.

A Co-founder of Apple has reported that his new organization is moving towards the objective of building the ‘Google maps of space’.

It wasn’t too quite a while in the past that a prime supporter of Apple declared he was joining the private space industry with an organization called Privateer.

Continue reading “Google Maps of the Cosmos is now in the development stage” | >

AI & computational technology for improving drug discovery & development — mati gill, CEO, AION labs.

Mati Gill is the Chief Executive Officer, of AION Labs (https://aionlabs.com/), a company recently launched and backed by a coalition of pharma and tech leaders, including AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services (AWS), and the Israel Biotech Fund (IBF) and Israel Innovation Authority, to improve the whole drug discovery & drug development process with AI and computational biology.

Mati has an MBA (Healthcare & Innovation) and BS degree in law from Reichman University / IDC Herzliya, and has over a decade of experience in leadership roles in the biopharma industry, including most recently as Head of Government Affairs, Corporate & International Markets, at Teva Pharmaceuticals.

Continue reading “Mati Gill, CEO, AION Labs — AI & Computational Technology For Improving Drug Discovery & Development” | >